Amitava Mitra

机构：Kura Oncology (United States)

发表论文 72 篇 · 总被引 3000 次 · h-index 33

代表论文

• Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial (2024 · The Lancet Oncology · 被引 105)
• Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report (2024 · Molecular Pharmaceutics · 被引 62)
• Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies (2021 · Journal of Pharmaceutical Sciences · 被引 61)
• Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview (2022 · Pharmaceutical Research · 被引 53)
• Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report (2024 · Molecular Pharmaceutics · 被引 34)
• Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML (2025 · Journal of Clinical Oncology · 被引 33)